A new era in the treatment of age-related macular degeneration: from Factor X to antiangiogenesis

Author： Gamulescu Maria-Andreea Helbig Horst

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.17, Iss.11, 2007-11, pp. : 1351-1363

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New therapies for the treatment of age-related macular degeneration

By Sarrafizadeh R. Trese M.T.

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 3, 2000-03 ,pp. : 333-341

Informa Healthcare

Access to resources Recommend Favorite

By Lacour M.

Drugs & Aging, Vol. 19, Iss. 2, 2002-02 ,pp. : 101-133

Adis International

Access to resources Recommend Favorite

Treatment and Prevention of Age‐Related Macular Degeneration

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 34, Iss. 1, 2004-03 ,pp. : 53-57

John Wiley & Sons Inc

Access to resources Recommend Favorite

Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration: What is the Evidence?

By Ziemssen Focke

Drugs & Aging, Vol. 26, Iss. 4, 2009-05 ,pp. : 295-320

Adis International

Access to resources Recommend Favorite

The Burden of Age-Related Macular Degeneration

By Schmier Jordana K. Jones Mechelle L. Halpern Michael T.

PharmacoEconomics, Vol. 24, Iss. 4, 2006-01 ,pp. : 319-334

Adis International

Access to resources Recommend Favorite